Abstrakt
L-Asparaginase is a drug commonly used in the therapy of childhood lymphoblastic leukaemias. A higher sensitivity to L-Asparaginase has been detected in patients with TEL/AML1 fusion gene.
This genotypically-defined group is distinguished by a good response to the therapy, yet relapses still occur in 17% of children. L-asparaginase depletes asparagines and glutamine from extracellular enviroment.
The activity of asparagine synthetase that synthesizes these amino acids is reduced in leukaemic cells. This paper, as well as some previous studies, paradoxically proves increased expression of asparagine synthetase in TEL/AML1[+] patients.
The authors have carried out a deep analysis of the biochemical cascade that affects the synthesis of asparagine and glutamine in malignant lymphoid cells. The analysis of expression profiling data from patients with acute lymphoblastic leukaemias have showed significantly decreased gene expression of glutamate dehydrogenase in TEL/AML1[+] patients, as compared with TEL/AML1[-] patients.
This phenomenon has also been confirmed by quantitative real-time PCR. The authors assume that an insufficient function of glutamate dehydrogenase leads to an insufficient synthesis of glutamine in the cell, leading to an increased expression of asparagine synthetase gene.
The cellular metabolism's ability to react to the limited asparagine and glutamine intake from extracellular enviroment following the administration of LAsparaginase is thus weakened. An explanation of the higher sensitivity to L-Asparaginase of the specific subgroup of patients could affect existing therapeutical procedures.